Abstract
from two clinical trials, in adults and children [12] . We use the adult data to obtain the PK 69 model of mefloquine in adults, and leverage this information for children through allometric 70 and maturation functions taking into account changes in body size and metabolic processes 71 with age [13] . We then use the extrapolated model to design a study for a paediatric 72 population with different age groups. We show that this approach provides a framework 73 that may dramatically improve the design of a PK study in children, allowing for a precise 74 estimation of PK parameters while limiting the number of sampling measurements.
75

Methods
76
In the present work, we considered the following methodological workflow, summarised 77 in Figure 1 . First, based on data collected in an adult population, we built a PK model.
78
Extrapolation using allometry and maturation was then applied to the resulting model in 
where f is a mathematical function representing the evolution of the concentration with 117 time. The vector φ i is the vector of individual parameters for i and ε i a n i -vector of random 118 errors distributed as ε i ∼ N (0, Σ i ). We assume that the distribution of the parameters can i :
The distribution of the random effects was assumed to be multivariate normal, with a 123 variance-covariance matrix denoted Ω 2 .
124
The parameters of the NLME model were estimated using the stochastic approximation whether Ω 2 could be assumed to be diagonal or not, and finally the residual variability.
131
Different residual error models were considered: a constant error model Var(ε i j ) = a 2 , a 132 proportional error model Var(ε i j ) = b 2 × f (φ i ,t i j ) 2 and a combined error model Var(ε i j ) =
133
(a + b f (φ i ,t i j )) 2 . In order to evaluate the stability of the estimates, the run assessment Fisher information matrix. The predictive ability of (M ad ) was evaluated by computing the 147 bias and root mean square errors (RMSE) between predicted and observed concentrations:
7 whereμ are the estimated population parameters and Var( f (μ,t i j )) = ∑ N i=1
) 2 is the variance of the predicted concentrations.
150
Extrapolation from adults to children
151
M ad , the PK model developed in adults was then modified to adjust to the children pop-152 ulation. The same structural model was left unchanged, but we scaled the values of 153 the parameters using either allometry alone (M allo ) or both allometry and maturation
154
(M allo+mat ), as detailed in the rest of this section.
155
Body size is a major determinant of metabolic rates, diffusion and transfer processes,
156
as well as organ size, throughout the animal kingdom and beyond. Allometric theory 157 models these processes throughout fractal geometry, and proposes a general scaling for 158 many processes [19] . Denoting BW the body size, a parameter µ would vary as:
where α is a constant characterising the type of organism, and β a scaling component.
160
In particular, volumes of distribution tend to increase linearly with size (β = 1) while 161 clearances, which are related to blood flow, increase non-linearly with a coefficient 3/4 162 (β = 0.75) derived from geometric considerations.
163
Model M allo was derived from M ad by introducing allometry in the population value 164 of the parameters to account for size, through the relationship:
8 where BW adult is the mean adult weight and BW child is the mean body weight of a given 166 child, β is 0.75 for clearances and 1 for volumes.
167
However, size differences do not explain all the variations between adults and children.
168
Many physiological processes evolve slowly towards adult functionality during childhood.
169
Model M allo+mat was developed from the allometric model M allo , by introducing a matura-
170
tion factor K mat,child in the previous equation:
Maturation is highly correlated with age, and has been studied for many physiological 172 processes, including absorption, first-pass effect, metabolism and transport. We derived 173 maturation equations for mefloquine, and used them to adjust individual clearances and 174 volumes in each child. These equations are described in the Appendix.
175
For both M allo and M allo+mat , we assumed the same interindividual variability for all 176 parameters, as well as the same residual errors, as those estimated in the adult populations.
177
Because in this work we had access to paediatric data, we used it as an external 178 evaluation dataset to assess the extrapolation process for both M allo and M allo+mat . The 179 predictive capacity of these two models was evaluated by computing bias and RMSE
180
on the paediatric data. We also evaluated the predictive capacity of the model without
Optimal design for a paediatric population
185
Design optimisation was performed for the model using both allometry and maturation 
211
The resulting optimal design is exact, with fixed days, which may be difficult to 212 implement. We can relax this assumption by using sampling windows, to add flexibility 213 to the practical implementation. As this cannot be implemented prospectively in PFIM,
214
we derived sensible windows for the optimised design assuming the patients can come in 215 anytime during daytime, and for several days on later visits.
216
Evaluation of paediatric design
217
To illustrate the expected performance and the robustness of the optimal paediatric design,
218
we evaluated its ability to estimate the PK parameters in children across a range of scenarios
219
corresponding to different models and model parameters, through a simulation study.
220
Figure 2 summarises the different stages of the evaluation.
221
We evaluated the design over the 4 different models previously introduced: (i) the 222 extrapolated model with maturation (M allo+mat ), which was used to optimise the design; compared to the theorical model value over the 100 simulations:
k is the estimate of the k th parameter in simulation l = 1, ..., L and θ k,th the 235 theoretical value.
236
The same simulations were also performed for the empirical design, to compare the 237 performance of the optimal design with the design that was in fact implemented in the 238 children study. The same parameters were used to simulate the concentrations in both 239 designs (optimal and empirical).
240
We also evaluated the performance of the design when relaxing the fixed times through 241 sampling windows. We again simulated 100 data sets, but this time the sampling times 242 for each visit were drawn according to a uniform distribution from the chosen sampling 243 windows. Evaluation was performed in a similar manner as for the optimal design.
244
3 Results Table 1 shows the demographic characteristics and biological measurements in the 247 adult (left) and paediatric (right) datasets used in the present analysis. The adult population 248 was almost exclusively male (1 woman), while the recruitment was more balanced in the 249 paediatric study (51 girls and 60 boys, 59% male).
250
[ mefloquine is administered once daily, followed by a slow bi-phasic decline.
257
In children, the design was more sparse and variable ( tal clearances, and the volumes of the two compartments, so that
The residual error was best described as a combined error model. We found that we could 268 remove the variability in V 2 from the model. This may be due to either a low interindi-
269
vidual variability for that parameter, or more likely, a lack of information to estimate that 270
parameter.
271 Table 2 shows the population parameters estimated for the adult model M ad . The resid- clearance Q had the highest interindividual variability.
275
There was no bias in predicting the adult concentrations (bias=0.06), showing no 276 systematic model misspecification, and the RMSE was estimated to be 1.14.
277
[ Extrapolation from adults to children
279
M ad was then used as a basis for individual extrapolation to the paediatric population,
280
yielding model M allo+mat .
281
Extrapolation was assessed using the paediatric data as an external evaluation dataset unidentifiable and the estimates of k a were unstable. Therefore, the absorption rate constant 296 k a was fixed to the value obtained in the adult population, without interindividual variability.
297
As expected, there was no bias for M ch (0.06); the precision measured by RMSE was 0.89.
298
The bias was significant for the three other models; the model with allometry M allo has in Optimal design for the paediatric population
306
M allo+mat was then used to design a sampling schedule for the paediatric population.
307
We first attempted to optimise designs with 3 or 4 sampling times, as this was close to the 308 design in the paediatric database, which we call empirical design. But optimisation failed, 309 indicating the model was not identifiable with so few samples. We therefore increased 310 the number of samples to 5 or 6. results in terms of RSE, suggesting that 5 sampling times were sufficient in our case.
318
The optimal design merged the 4 designs, and the corresponding times are given in the 319 last row of Table 3 .
320
[ Table 4 334 were computed over all the corresponding runs. As seen in the The objective of the present work was to design a pharmacokinetic paediatric study 365 using adult information in malaria. To this end, we investigated the impact of design on the 366 information gained from the children study, exploring models taking into account prior adult 367 information through extrapolation by allometry and maturation. We used the paediatric 368 data both as an external evaluation dataset and to suggest alternative models to test the 369 robustness of both the empirical design actually performed in children and the optimised design. We assessed their performance with regard to changes in parameter assumptions.
371
In the pharmacokinetic analysis in adults, a two-compartment model was found to best found in study [24] suggest that their design would also be quite robust.
446
We assessed the performance of the optimal design in a simulation study including four 
487
An interesting finding of our work is the message that the design need not be perfect,
488
as long as it is robust enough. As is always the case in optimal design, the model we are 489 trying to estimate is unknown prior to performing the study, but needs to be specified to 490 design that study, and the design will only be appropriate if the model is correct. A way Here, we used D-optimality, which relies on prior knowledge of the parameters, but we 498 could enhance robustness through ED-optimality, which allows to incorporate uncertainty 499 in the prior parameter specifications [39] . These methods could be investigated in order to 500 obtain more robust design in paediatrics studies, where parameters are usually unknown 501 and the inter-individual variability very high.
502
In our study, we used data from an adult population and extrapolated the estimated paediatric context and showed that such designs can correct initial model misspecifications.
508
In their work, the prior information on children was obtained by extrapolating to a children 509 population a PBPK model developed in adults and performing a population PK analysis on 510 simulated data from a virtual paediatric population, an alternative to extrapolation models.
511
In the present study we use repeated optimisation and simulation to evaluate the prior to the study to be taken into account both at the design stage and at the implementation 518 stage, it is a powerful way of ensuring that the constraints are well accepted and that the 519 design is applicable in practice.
520
In conclusion, the present work supports using adult prior information for design 
539
Molecules of mefloquine bind strongly with albumin (98% in adults), resulting in a slow 540 diffusion. The unbound molecules of mefloquine are metabolised by cytochrome CYP3A4.
541
Afterwards, mefloquine is eliminated through renal clearance.
542
These processes are slightly modified for children, due to ongoing maturation. abundance are characterised by their own maturation function [32] . Denoting K CY P3A the 559 maturation of CYP3A and K CY P3A4/5 the maturation of CYP3A4/5, the bioavailability for 560 children can be written:
With oral drugs, bioavailability is a key value in estimation of pharmacokinetic pa-562 rameters, which are estimated as apparent, that is relative to the bioavailability. Therefore,
563
it has an impact on all clearance and volume parameters. Let Cl ad the apparent adult 564 clearance related to the real clearance Cl ad,real through Cl ad = Cl ad,real /F ad where F ad 565 is the adult bioavailability. Likewise, we express the apparent clearance for children
566
Cl ch = Cl ch,real /F ch .
567
As for volume, we have V ad = V ad,real /F ad with V ad the apparent volume, V ad,real the real 568 27 volume. Likewise, for children, we have V ch = V ch,real /F ch .
569
In the blood stream, mefloquine binds strongly to albumin, leaving only a small 570 fraction of mefloquine unbound. Let f u,ch this fraction in children. While bound to albumin, 571 mefloquine can not be eliminated from the blood stream and only the unbound fraction can 572 be eliminated. Let Cl ch,u the clearance of the unbound fraction of mefloquine in the blood.
573
Therefore, we have:
574
Cl ch,real = Cl ch,u × f u,ch (
leading to:
In adults, 98% of mefloquine is bound to albumin, such that the adult unbound fraction 576 is f u,ad = 0.02. In children, the fraction of unbound mefloquine can be related to adult 577 unbound fraction of mefloquine f u,ad and to albumin concentration, which varies from C ad
578
(40 g/L on average) and the corresponding value in children, C ch , respectively [32] . The 579 following relationship links the unbound fraction of mefloquine in children to the albumin 580 concentration:
Moreover, albumin concentration in children can be expressed as a function of age [32] : 
As extraction coefficient are unknown for mefloquine, we arbitrary chose E gut = 592 E hepa = 0.5.
593
We then need to evaluate maturation of the cytochrome. 
